These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Reconstitution of high-level micafungin resistance detected in a clinical isolate of Candida glabrata identifies functional homozygosity in glucan synthase gene expression. Niimi K, Woods MA, Maki K, Nakayama H, Hatakenaka K, Chibana H, Ikeda F, Ueno K, Niimi M, Cannon RD, Monk BC. J Antimicrob Chemother; 2012 Jul; 67(7):1666-76. PubMed ID: 22514266 [Abstract] [Full Text] [Related]
4. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations. Lepak A, Castanheira M, Diekema D, Pfaller M, Andes D. Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870 [Abstract] [Full Text] [Related]
5. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Zimbeck AJ, Iqbal N, Ahlquist AM, Farley MM, Harrison LH, Chiller T, Lockhart SR. Antimicrob Agents Chemother; 2010 Dec; 54(12):5042-7. PubMed ID: 20837754 [Abstract] [Full Text] [Related]
8. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. Antimicrob Agents Chemother; 2009 Sep; 53(9):3690-9. PubMed ID: 19546367 [Abstract] [Full Text] [Related]
10. In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection. Fernández-Silva F, Lackner M, Capilla J, Mayayo E, Sutton D, Castanheira M, Fothergill AW, Lass-Flörl C, Guarro J. Antimicrob Agents Chemother; 2014 Jul; 58(7):3646-9. PubMed ID: 24733474 [Abstract] [Full Text] [Related]